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فقر الدم املنجلي لدى البالغني
جتربة مخس سنوات من العناية املركزة يف مستشفى جامعي يف ُعمان.
قتيبة عامر توفيق، راجيني كوزاليا، �سحى حممود علوان، جوتي براد، اأحمد خمي�س حممد، اأرفند نرايانان
االأكرث  الوراثية  الدم  الهيموغلوبني، وهو واحد من  ا�سطرابات  الدم املنجلي مر�س وراثي ناجم عن نوع غري طبيعي من  امللخ�ص: فقر 
�سيوعا يف منطقة اخلليج، مبا يف ذلك ُعمان. قد يح�سل م�ساعفات تتطلب العالج يف وحدة العناية املركزة. هذه الدرا�سة تبحث االأ�سباب 
التي اأدت اإىل اإدخال املر�سى امل�سابني بفقر الدم املنجلي وحدة العناية املركزة. الطريقة: هذه درا�سة ا�ستعادية جلميع املر�سى البالغني 
)12 �سنة اأو اأكرث( امل�سابني بفقر الدم املنجلي الذين رقدوا يف وحدة العناية املركزة مب�ست�سفى جامعة ال�سلطان قابو�س بني يناير 2005 
ودي�سمرب 2009. النتائج: مت اإح�ساء 56 حالة رقود ل 49 مري�سا يف وحدة العناية املركزة. �سملت اأ�سباب الرقود متالزمة ال�سدر احلادة 
)%69.6(، واالأزمات املوؤملة )%16.1(، ف�سل االأع�ساء املتعددة )%7.1( واأ�سباب اأخرى )%7.2(. كان معدل وفيات مر�سى فقر الدم 
العناية  وحدة  دخول  حني  اأ�س  والهيموجلوبني-  الهيموجلوبني  م�ستويات  درا�سة  مّت   .)16.1%( املركزة  العناية  يف  الراقدين  املنجلي 
املركزة لكن مل تظهر اأية داللة اإح�سائية معتّدة لهما يف فح�س )تي( لتوقع  الوفاة. مت ا�ستخدام ن�سبة االأرجحية مع فرتة الثقة )95%( 
لدرا�سة تدابري اأخرى داعمة ل�ستة اأع�ساء للتكّهن بالوفيات. كانت احلاجة للح�سول على دعم جهاز الدوران والتنف�س امليكانيكي موؤ�رض 
جيد للوفيات، يف حني اأن احلاجة اإىل التنف�س غري الغازي وتر�سيح الدم وعمليات نقل الدم وتبديل الدم ال تعترب ذات داللة كبرية للتكهن 
باحتماالت الوفاة. اخلال�صة: متالزمة ال�سدر احلادة هي ال�سبب الرئي�سي الإدخال مري�س فقر الدم املنجلي يف وحدة العناية املركزة. خالفا 
لغريها من االإجراءات الداعمة، ا�ستخدام الدعم جلهاز الدوران و/اأو التنف�س امليكانيكي هو موؤ�رض على ارتفاع معدل وفيات هوؤالء املر�سى.
مفتاح الكلمات: فقر الدم، خلية منجلية، متالزمة ال�سدر احلادة، ُعمان.
abstract: Objectives: Sickle cell disease (SCD) is an inherited disease caused by an abnormal type of haemoglobin. 
It is one of the most common genetic blood disorders in the Gulf area, including Oman. It may be associated with 
complications requiring intensive care unit (ICU) admission. This study investigated the causes of ICU admission 
for SCD patients. Methods: This was a retrospective analysis of all adult patients ≥12 years old with SCD admitted 
to Sultan Qaboos University Hospital (SQUH) ICU between 1st January 2005 and 31st December 2009. Results: 
A total number of 49 sickle cell patients were admitted 56 times to ICU. The reasons for admission were acute 
chest syndrome (69.6%), painful crises (16.1%), multi-organ failure (7.1%) and others (7.2%). The mortality for SCD 
patients in our ICU was 16.1%. The haemoglobin (Hb) and Hb S levels at time of ICU admission were studied as 
predictors of mortality and neither showed statistical significance by Student’s t-test. The odds ratio, with 95% 
confidence intervals, was used to study other six organ supportive measures as predictors of mortality. The need 
for inotropic support and mechanical ventilation was a good predictor of mortality. While the need for non-
invasive ventilation, haemofiltration, blood transfusions and exchange transfusions were not significant predictors 
of mortality. Conclusion: Acute chest syndrome is the main cause of ICU admission in SCD patient. Unlike other 
supportive measures, the use of inotropic support and/or mechanical ventilation is an indicator of high mortality 
rate SCD patient.
Keywords:  Anemia; Sickle cell; Acute chest syndrome; Oman.
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Advances in knowledge 
- This study gives a descriptive analysis for sickle cell patients admitted to an intensive care unit.
- It validates the rate and causes of sickle cell patients’ admission to intensive care unit.
- The need for inotropic support and mechanical ventilation are the main mortality predictors for sickle cell patient in an intensive care 
unit.
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Sickle cell disease (SCD) is an autosomal recessive disease caused by an abnormal type of haemoglobin, termed 
haemoglobin S (Hb S).This haemoglobin is caused 
by the substitution of valine for glutamic acid at 
the sixth amino acid position of the beta chain.1, 2 
There is more than one form of sickle cell disease 
resulting from coinheritance of Hb S with other 
abnormal Hb variants. Sickle cell anaemia (Hb SS) 
is the commonest form in the USA. Other forms 
include, Hb Sβ+-thalassaemia, Hb SD Hb SC. 
There are rare forms result from coinheritance of 
other Hb variants such as D-Punjab and O-Arab 
with Hb S.1 SCD is much more common in certain 
ethnic groups and it is considered as one of the 
most common genetic blood disorders in the Gulf 
area, including Oman.2 In Oman, the incidence 
of sickle cell disease and sickle cell trait in Omani 
neonates was 0.3% and 4.8% respectively.3Although 
the SCD manifestations per se do not typically 
necessitate critical care management, several life-
threatening complications may require intensive 
care unit (ICU) admission. Some patients have 
repeated crises, which can result in damage to 
different organs or systems. The most common 
complications associated with SCD include vaso-
occlusive pain crises (VOC), acute chest syndrome, 
severe anaemia, infection, cerebral vascular 
accidents, and multiorgan failure.4,5 Because of 
the fact that there has been little progress in fully 
understanding the pathophysiology of SCD and 
finding a cure for it, our management is primarily 
focusing on treating the negative sequelae and 
complications of the disease.6,7 This study was a 
descriptive analysis of sickle cell patients who were 
admitted with complications to the ICU at Sultan 
Qaboos University Hospital, Oman, over five years 
and investigated the predictive factors for sickle cell 
mortality.
Methods  
This study was a retrospective analysis of all 
adult patients ≥12 years with SCD admitted to 
the SQUH ICU between 1st January 2005 and 31st 
December 2009. The study was approved by both 
the institution’s Medical Research Committee 
and its Ethics Committee. SQUH is a tertiary 
care, teaching hospital with a 12-bed ICU and 
haematology ward. Data were collected from the 
SQUH information system (HIS) and its electronic 
patient records (EPR) as well as the SQUH intensive 
care database. Information collected included 
presentation, co-morbidities, organ failure, organ 
support, length of stay in the ICU, and final 
outcome. Eight factors were studied as predictors 
for mortality for SCD in ICU. These included 
Hb and Hb S levels in addition to six methods of 
organ support: inotropes, invasive ventilation, non-
invasive positive pressure ventilation (NIPPV), 
haemodialysis/ haemofiltration, blood transfusion 
and exchange transfusions. The Student’s t-test was 
used for continuous/ordinary variables, while odds 
ratios (ORs), with 95% confidence intervals (CIs) 
were used to assess binary variables.
Results
A total of 49 sickle cell patients were admitted 56 
times to the ICU; 25 of those admissions (44.6%) 
were female patients. Two patients had three 
admissions while three patients had two admissions 
each. The range of patients’ ages was 12 and 52 years, 
with median of 27 years. Our ICU admits patients 
≥ 16 years old, but our protocol allows admission of 
specific surgical cases and trauma down to the age 
of 12 years.
Acute chest syndrome was the commonest 
reason for admission (n = 39, 69.6%) [Table 1]. 
Painful crises were the principal cause of admission 
for 9 patients (16.1%). However, VOC was present 
in another 16 cases in association with other major 
complaints like acute chest syndrome (ACS). Multi-
organ failure (MOF) was the cause of admission in 
4 patients (7.1%). 
Neurological complications related to SCD 
were found in 2 patients (3.57%). One patient 
Application to patient care 
- This study will improve sickle cell patient care in intensive care units by understanding causes of admission, complications, length of stay 
and mortality.
- It helps in realising the modes of organ support required for those patients.
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was transferred intubated from another hospital 
with radiological features of cerebral ischaemia 
and anoxic brain injury. The other patient had a 
subarachnoid haemorrhage.
One patient was admitted with hepatic failure 
associated with hepato-renal shutdown and 
features of hepatic encephalopathy (1.8%). Another 
12-year-old patient was admitted to our adult ICU 
as a surgical case after laparoscopic splenectomy 
and cholecystectomy with sever intra-operative 
haemorrhage. 
Eight patients were admitted through the 
Emergency department (14.28%) in comparison 
to 46 admissions (83.9%) from the ward. Only 
one patient (1.78%) was referred, intubated, from 
another hospital directly to our ICU. 
The mortality for SCD in our ICU was 16.07% (9 
patients), comparable to an ICU-overall mortality of 
21.1% during the same period in the same institute. 
Five cases were admitted with ACS and four cases 
with MOF.
The length of stay in the ICU ranged from 1 to 
23 days. For survivors, the mean lengths of ICU stay 
was 5 days, while for non-survivors it was 2.7 days. 
This is considered to be statistically significant (P = 
0.04). 
A total of 27 admissions for those who survived 
were with those with no co-morbidities (57.4%) 
in comparison to 4 admissions among those who 
died (44 %). The survivors’ co-morbidities can be 
classified into: Behcet’s disease (1); autoimmune 
disease (1); hepatitis (C and/or B) virus (5); liver 
cirrhosis (1); osteoporosis with avascular necrosis 
of one or more joint (6); glucose-6-phosphate 
dehydrogenase (G6PD) deficiency (4); nephrotic 
syndrome (2); asthma (2); chronic renal failure (2), 
and  protein C deficiency with cerebral ischaemia 
(1). Four admissions were pregnant patients. 
It should be taken in consideration that some 
patients had more than one medical problem or co-
morbidity at the time of admission.
Co-morbidities in non-survivors can be 
classified into: congenital neutropenia (1); dilated 
cardio-myopathy (1); systemic lupus erythematosus 
associated with chronic renal failure (2), and 
nephrotic syndrome (1).
In the ICU, the level of Hb and Hb S at the time 
of admission was studied as a predictor of mortality. 
The mean Hb for both, survivors and non-survivors 
were similar (8.3mg/dl and 8.6mg/dl, respectively). 
The range of Hb was (4.4–12.5 gm/dl) for those who 
survived and (6.4–11.2gm/dl) for non survivors. 
This result is not statistically significant (P = 0.8).
For those who survived, the Hb S mean for 36 
cases was 63% with standard deviation (SD) 21.5 
(11 not available), while for non-survivors the mean 
Hb S for 7 admissions was 54.5% (2 not available) 
with SD 25.5. This result is also not statistically 
significant by t-test (P = 0.4). High-performance 
liquid chromatography (HPLC) was used to 
study Hb S through Bio-Rad variant II (Bio-Rad 
Laboratories, Inc., Hercules, California, USA).
 Most of the patients in this study were admitted 
for some time in the ward and received simple or 
exchange blood transfusions before coming to the 
ICU.
The odds ratio (OR), with 95% CIs, was used 
to study the six organ supportive measures as 
a predictive for the increase in mortality [Table 
2]. These supportive measures include the 
use of inotropes, invasive ventilation, NIPPV, 
haemodialysis/ haemofiltration, exchange 
transfusion and top-up blood transfusions.
Requirement for inotropes was a good predictive 
for mortality (OR 117.3). It means that mortality 
is much more likely in SCD patient who require 
cardiovascular support in the form of inotropes. 
Eight of the 9 patients who died required inotropes. 
Four of those patients had MOF and another 4 
ACS. Three of 47 patients who survived required 
inotropic support. All the three were admitted with 
ACS.
Invasive mechanical ventilation (MV) was 
similarly a good predictive for mortality as 8 of 9 
patients who died required MV while another 
8 required MV among those who survived (OR 
39). Regarding those who required intubation and 
Table 1: Causes of intensive care unit admission for 
sickle cell patients.
Cause of admission Number 
(N = 56)
Percentage
Acute chest syndrome 39 69.6
Painful crises 9 16.1
Multi-organ failure 4 7.1
Brain insult 2  3.6
Hepatic failure 1 1.8
Surgical cause 1 1.8
Adult Sickle Cell Disease 
A Five-year Experience of Intensive Care Management in a University Hospital in Oman
180 | SQU Medical Journal, May 2012, Volume 12, Issue 2
mechanical ventilation among non-survivors, 4 
of them had MOF and the other 4 had ACS. Of 
those who survived, one patient was admitted for 
subarachnoid haemorrhage, one patient for cerebral 
ischaemia and anoxic brain injury (ended with 
tracheostomy), another patient post laparoscopic 
surgery, and all others with ACS.
NIPPV was studied as a predictor for mortality 
(OR 0.09). This ratio illustrates that mortality was 
very unlikely in those patients who have SCD 
and do require NIPPV. NIPPV was required in 28 
admissions (27 survived). The only patient who died 
was a case of ACS who had a sudden cardiac arrest 
while he was on NIPPV. 
Simple blood transfusion was used to support 
35 SCD admissions in ICU (62.5%). A total of 29 
of them survived while 6 died. The need for blood 
transfusion was not considered as a very good 
predictor for mortality (OR 1.2). Blood exchange 
transfusion was used in 45 admissions (80.4%), 7 of 
them died. The need for exchange transfusion does 
not predict mortality (OR 0.8).
Continuous veno-venous haemodialysis 
(CVVHD) was used in 8 admissions; four of them 
died (OR 8.6). Two of those who died were admitted 
because of ACS as a part of generalised VOC and 
they developed acute renal failure. The other two 
were admitted with systemic lupus erythmatosus 
and chronic renal failure. For the 4 admissions that 
had acute renal failure and survived, 3 had ACS and 
one had hepato-renal shutdown. 
As haemodialysis was used for both acute and 
chronic renal failure, it was not considered a good 
indicator of severe acute illness and mortality
Discussion
Sickle cell vaso-occlusion may involve both the 
micro- and macrovasculature. It is the most 
important pathophysiologic event in SCD and 
explains most of its clinical manifestation. The 
median age at death in patient with SCD is 42 years 
for males and 48 years for females.8
Acute chest syndrome (ACS) is a common cause 
of admission and death among patients with sickle 
cell disease. ACS is usually caused by infection, 
pulmonary infarction or fat embolism. Painful crisis 
is the main cause of admission in those patients 
(90%). To reach a diagnosis of ACS, we need a triad 
of fever, respiratory distress and new interstitial 
infiltrates on chest X-ray.9,10,11
This study represents the first data collection 
and analysis of sickle cell patients admitted to an 
ICU in Oman. In SQUH, the adult 12 bed ICU 
admits both medical and surgical cases including 
trauma patients. We admit some of those patients 
who require non-invasive ventilation (NIV) as 
well because our high dependency units (HDU) 
setting is not completed. We also sometimes accept 
paediatric trauma or post surgical patients ≥ 12 
years for specific reasons. Over five years there 
were 56 SCD admissions which represent 3.5% of 
total admissions in our ICU. We referred to our 
patients as sickle cell disease patients depending on 
their high Hb S level, although genotyping studies 
are required for all patients to confirm the Hb SS or 
other sickle cell types of Hb. A retrospective study 
in the UK reported that Hb SS was found in 84% 
of their ICU admission while the other 16% was 
Hb SC.12 This might possibly refer to the severity 
of disease expression in patients having this type of 
haemoglobin. All sickle cell patients’ admissions, 
except one, were for medical reasons. Two patients 
had 3 repeated admissions while three patients 
had 2 admissions each. These repeated admissions 
were divided between ACS and painful crisis. No 
mortality was reported among those who had 
repeated admissions.
It was sometimes difficult to choose a single 
reason for admission as some patients may have a 
complex clinical presentation with more than one 
complaint and more than one organ involved. This 
complexity may be related to the nature of SCD and 
the sickling process. ACS was the most common 
cause of admission (69.6% in our ICU) compared to 
Table 2: Types of organ support needed by patients 
admitted to the intensive care unit.




















4:43 4:5 Not 
Identified
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30% in Gardner’s study.12 All those patients required 
ventilatory support whether it was invasive or non-
invasive. In our study, MOF (4 patients) was the 
third cause of admission after painful crisis with a 
rate of 7.1%, compared to 17% in Gardner’s study.12 
The mortality rate for sickle cell patients in our 
study was less than the overall mortality in our ICU 
(16.1% versus 21.1%). Gardner et al. reported a 
higher ICU sickle cell patient mortality compared to 
overall ICU mortality in the same period and same 
institute (19.6% versus 17.6%).12 We can explain this 
difference by the cases of painful crises (9 admissions) 
in our study in which no death was reported, while 
in the British study there were no painful crises as 
a cause of admission. In fact, cases of painful crisis 
can be treated in the ward or in HDU if no other 
organ support measures are required. According 
to our hospital protocol, patients who require ICU 
admission are those on very high doses of opioid 
infusion with no response, those with compromised 
cardiovascular or respiratory functions, and those 
who require additional ketamine infusion. We agree 
that if there is a well-structured HDU, admission of 
those cases to an ICU can be avoided.
Two main causes of death in ICU sickle cell 
patients were found in our study [Table 3]: ACS (5 
patients, 55.6%) and MOF (4 patients, 44.4%). Three 
of those ACS patients stayed for less than one day 
and one patient died after 3 days after admission. 
Regarding the four MOF patients who died, two 
deaths were triggered by ACS while another two 
were associated with sepsis. 
Gardner et al. found that MOF and stroke 
(haemorrhage/ischaemia) were the main causes of 
death in sickle cell patients in their ICU, 33.3% for 
each condition. ACS was next commonest cause 
with a rate of 22.2% while trauma caused death in 
11.1% of cases.12 A review of the causes of death in 
adult patients (age >20 years) with sickle-cell disease 
in Jamaica by Thomas et al. showed that ACS was 
responsible for 22% of death in those patients. 
Other common causes of death in Jamaican sickle 
cell patients were renal failure 15.7%, pregnancy-
related problems 7.4% and sepsis 3.7%.13
The length of stay in the ICU ranged from 1 to 23 
days. For non-survivors, 4 of 9 patients (44%) stayed 
for less than 24 hours. One patient with a history 
of dilated cardiomyopathy was admitted from the 
Emergency department with MOF. The other 3 
patients were admitted from the ward with VOC/
ACS and suddenly deteriorated. One of them had 
clinical and echocardiographic features suggestive 
of pulmonary embolism (no spiral computed 
tomography [CT]). The other two had an element 
of sepsis in addition to ACS. This result can be 
referred to the nature and complexity of the disease 
with possibility of rapid deterioration in some cases. 
The other explanation may be the possibility of 
delay of ICU admission to give intensive supportive 
measures especially for patient with features of 
sepsis.
The majority of the cases (83.9%) had been 















19/M 8.8 48.4  Nil 2 Sepsis, MOF I, V, B, E
28/F 8.7 36.2 Nil 8 ACS, MOF I,V,B, H
19/M 9.6 NA SLE, CRF, Congenital 
neutropenia
1 ACS/PE? I,V, E
22/F 7.2 36.5 SLE, CRF 2 Sepsis, MOF I, V, B, E, H
31/F 6.4 NA SLE, nephrotic syndrome 1 ACS, sepsis I, V, B, E
53/F 7.9 33.2 Nephrotic syndrome. 3 ACS/PE? I, V, B, H
19/F 7.7 91.9 Nil 3 ACS, sepsis I, V, B, E, H
28/F 9.9 77.8 Nil 1 ACS NIV, E
30/M 11.2 89.6 Dilated cardiomyopathy 1 ACS, MOF I, V, E
Legend: M = male; F = female; MOF = multi organ failure; I = inotropes; V = mechanical ventilation;  B = blood transfusion; E = exchange 
transfusion; ACS = acute chest syndrome; H = haemodialysis; SLE = systemic lupus erythematosus; CRF = chronic renal failure;  PE = pulmonary 
embolism; Nil = no co-morbidities, NIV = non-invasive ventilation.
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admitted to the ward for some time before being 
moved to our ICU. Those patients received 
all necessary supportive measures in the ward 
including blood transfusion and exchange 
transfusion depending on their length of stay. This 
may mask the role of Hb and Hb S level at the 
time of ICU admission as an indicator for severity 
of the crises or even mortality. However, simple 
and exchange transfusions were performed as 
supportive measures in 62.5% and 80.4% of ICU 
admissions respectively depending on base line Hb 
and Hb S levels and the patient’s general condition.
The main aim of red blood cell (RBC) 
transfusion in SCD is to prevent and resolve vaso-
occlusive events that result in ACS, stroke, and 
other ischaemic organ damages. This transfusion 
can be chronic or intermittent. The effect of RBC 
transfusion is improving the oxygen-carrying 
capacity; lowering blood viscosity; diluting the 
concentration of Hb S, and suppressing production 
of sickle RBCs due to the improvement in tissue 
oxygenation.14,15 The indications for intermittent 
RBC transfusion include: acute symptomatic 
anaemia; sequestration crisis; aplastic crisis; acute 
stroke; ACS; sepsis; acute multiorgan failure, and 
preparation for general anesthesia or ophthalmic 
surgeries.14 Simple transfusion is more convenient 
and easier than exchange transfusion and it is 
more frequently used for acute transfusion, but 
exchange transfusion is a good option in an acute 
crisis patient with a higher pretransfusion Hb level 
or when volume overload and hyperviscosity are of 
particular concern.16
One of the therapeutic aims of exchange 
transfusion in vaso-occlusive event like ACS is to 
decrease the proportion of erythrocytes containing 
Hb S to less than 30%, thereby improving 
microvascular perfusion. Two volumes of red cell 
exchange transfusion decrease HbS containing red 
blood cells to less than 20%. However, a reduction 
in Hb S levels may not be the only explanation 
for the early and dramatic clinical improvement 
often demonstrated in patients with ACS after 
exchange transfusion. This is because neutrophils 
and platelets, which are inflammation markers, 
may contribute to venous stasis in the pulmonary 
microcirculation.14,15 Alhashimi D et al., during their 
Cochrane review, found that there is no reliable 
evidence to support or refute the effectiveness of 
simple or exchange blood transfusions in treating 
ACS.17 
Inotropic support was required in 88.9% of 
those who did not survive in comparison to 6.4% in 
survivors. It is clear that this difference is basically 
related to the seriousness of the clinical condition 
and the presence of elements of sepsis and MOF 
in most of non-survivors. The same facts can be 
applied to invasive ventilation as it was required 
in 88.9% in non-survivors compared with 17% for 
those who survived. Patients who required one 
or both of these organ supports have a significant 
higher risk of mortality. By contrast, non-invasive 
ventilation (NIV) does not carry that risk as it is 
usually used for more stable patients with ACS who 
require some ventilatory support.
ACS may be triggered in SCD by infection. 
Usually the clinical presentation is similar whether 
it is due to infectious or non-infectious causes. 
Therefore, antibiotics can be considered as one 
of the supportive measures for those patients. 
Antibiotic cover as a line of treatment for those 
patients was not included in detail in our study.18
Finally, there are some limitations to this 
retrospective study. The sample size was not large; 
this might be overcome in future research by 
including multicentre data. The other point was 
the difficulty in assessing the direct effect of the 
co-morbidities on mortality. The third point was 
related to our hospital ICU protocol, which led to 
admitting some categories of sickle cell patients 
who would normally be treated in an HDU rather 
than an ICU.
Conclusion
SCD is a common haematological problem 
in Oman. ACS was the main reason for ICU 
admissions in our study. The mortality for SCD 
was slightly less than the overall ICU mortality 
during the same period. The need for inotropes 
and invasive ventilation were considered the main 
predictors of mortality. On the other hand, the 
need for non-invasive ventilation, haemofiltration, 
blood transfusions and exchange transfusions were 
not significant predictors of mortality.
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